Clinical Trial Update: ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abemaciclib in combination with hydroxychloroquine to target minimal residual disease in breast cancer. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Plaquenil (hydroxychloroquine)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING